DK1237559T3 - Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran - Google Patents

Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran

Info

Publication number
DK1237559T3
DK1237559T3 DK00982033T DK00982033T DK1237559T3 DK 1237559 T3 DK1237559 T3 DK 1237559T3 DK 00982033 T DK00982033 T DK 00982033T DK 00982033 T DK00982033 T DK 00982033T DK 1237559 T3 DK1237559 T3 DK 1237559T3
Authority
DK
Denmark
Prior art keywords
melagatran
receptor antagonist
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
DK00982033T
Other languages
English (en)
Inventor
John Dixon
Robert Humphries
Gavin Jarvis
Ian Kirk
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1237559T3 publication Critical patent/DK1237559T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00982033T 1999-12-01 2000-11-29 Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran DK1237559T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
DK1237559T3 true DK1237559T3 (da) 2006-10-30

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00982033T DK1237559T3 (da) 1999-12-01 2000-11-29 Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran

Country Status (33)

Country Link
US (2) US20030032618A1 (da)
EP (2) EP1719526A3 (da)
JP (1) JP2003515565A (da)
KR (1) KR100785953B1 (da)
CN (1) CN1402639A (da)
AR (1) AR033658A1 (da)
AT (1) ATE332698T1 (da)
AU (1) AU781691B2 (da)
BR (1) BR0016043A (da)
CA (1) CA2391161C (da)
CO (1) CO5271717A1 (da)
CY (1) CY1105211T1 (da)
CZ (1) CZ300925B6 (da)
DE (1) DE60029340T2 (da)
DK (1) DK1237559T3 (da)
EE (1) EE05127B1 (da)
ES (1) ES2267591T3 (da)
HK (1) HK1047893A1 (da)
HU (1) HU230890B1 (da)
IL (1) IL149495A0 (da)
IS (1) IS2841B (da)
MX (1) MXPA02004871A (da)
MY (1) MY128896A (da)
NO (1) NO331215B1 (da)
NZ (2) NZ518904A (da)
PT (1) PT1237559E (da)
RU (1) RU2242232C2 (da)
SE (1) SE9904377D0 (da)
SI (1) SI1237559T1 (da)
SK (1) SK288707B6 (da)
TW (1) TWI251491B (da)
WO (1) WO2001039781A1 (da)
ZA (1) ZA200203707B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
KR100736024B1 (ko) * 2005-09-21 2007-07-06 주식회사종근당 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
PL2964233T3 (pl) 2013-03-09 2022-04-25 Chiesi Farmaceutici S.P.A. Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych
KR20200018481A (ko) 2017-06-23 2020-02-19 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
DK0508687T3 (da) * 1991-04-06 1996-02-05 Astra Pharma Prod ATP-analoger
HU221501B (en) * 1993-02-10 2002-10-28 Astrazeneca Ab N-alkyl-2-substituted atp analogues
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE69621021T2 (de) * 1995-07-11 2002-10-31 Astrazeneca Ab Inhibitoren der plättchenaggregation
ES2246575T3 (es) * 1998-06-17 2006-02-16 Bristol-Myers Squibb Company Prevencion del infarto cerebral mediante la administracion de una combinacion de un farmaco antiplaquetario bloqueador del receptor adp y un farmaco antihipertensivo.
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
CA2532805A1 (en) * 2003-07-16 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
JP2003515565A (ja) 2003-05-07
CZ300925B6 (cs) 2009-09-09
RU2242232C2 (ru) 2004-12-20
SE9904377D0 (sv) 1999-12-01
RU2002117296A (ru) 2004-01-20
ES2267591T3 (es) 2007-03-16
CN1402639A (zh) 2003-03-12
NO20022606L (no) 2002-07-11
HUP0203585A2 (hu) 2003-03-28
CY1105211T1 (el) 2010-03-03
TWI251491B (en) 2006-03-21
HU230890B1 (hu) 2018-12-28
CO5271717A1 (es) 2003-04-30
EE200200271A (et) 2003-06-16
AU781691B2 (en) 2005-06-09
CA2391161A1 (en) 2001-06-07
PL355841A1 (en) 2004-05-17
US20060270607A1 (en) 2006-11-30
PT1237559E (pt) 2006-10-31
CZ20021887A3 (cs) 2002-11-13
KR100785953B1 (ko) 2007-12-14
HUP0203585A3 (en) 2005-01-28
SK288707B6 (sk) 2019-10-02
CA2391161C (en) 2010-10-05
IL149495A0 (en) 2004-03-28
SK7502002A3 (en) 2003-02-04
EP1237559A1 (en) 2002-09-11
NZ518904A (en) 2004-02-27
NO331215B1 (no) 2011-11-07
DE60029340D1 (de) 2006-08-24
DE60029340T2 (de) 2007-07-19
EP1719526A2 (en) 2006-11-08
AU1910901A (en) 2001-06-12
BR0016043A (pt) 2002-07-23
ATE332698T1 (de) 2006-08-15
MY128896A (en) 2007-02-28
KR20020069201A (ko) 2002-08-29
ZA200203707B (en) 2003-10-29
NZ530058A (en) 2005-04-29
MXPA02004871A (es) 2002-08-30
WO2001039781A1 (en) 2001-06-07
NO20022606D0 (no) 2002-05-31
AR033658A1 (es) 2004-01-07
IS6398A (is) 2002-05-27
EE05127B1 (et) 2009-02-16
IS2841B (is) 2013-08-15
HK1047893A1 (en) 2003-03-14
EP1237559B1 (en) 2006-07-12
SI1237559T1 (sl) 2007-02-28
US20030032618A1 (en) 2003-02-13
EP1719526A3 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
DK1237559T3 (da) Farmaceutiske kombinationer som omfatter en P2T-receptor-antagonist og melagatran
IS7324A (is) Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
DE50014244D1 (de) Pharmazeutische tramadolsalze
NO20021719D0 (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
EE03855B1 (et) Alfusosiinhüdrokloriidi reguleeritult vabastav tablett
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20020859D0 (no) PH-1, en reseptor for B7-4 og anvendelser derav
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20015931D0 (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
IL146632A0 (en) Pharmaceutical tablets
DK1275397T3 (da) Lægemiddel til lokal anvendelse
ATE305920T1 (de) Bradykinin receptorantagoniste
NL1017143A1 (nl) Glazen voorwerp en glassubstraat voor een beeldplaat.
NO990243L (no) Trovafloxacin-mesylat-tablett
AU2001271435A1 (en) Vitronectin receptor antagonist pharmaceuticals
NO20013997D0 (no) Reseptoranalyse
IS6723A (is) 10-arýl-11H-bensó[b]flúorenafleiður og hliðstæðurtil lyfjanotkunar
NO20035798L (no) Tablett som inneholder cetirizin og pseudoefedrin
NO20014224L (no) 4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
IS6163A (is) Lyfjakomplex
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
NO991359D0 (no) Tablettdispenser
DK1421115T3 (da) Oplöselig T-cellereceptor